| Dysregulated serum response factor triggers formation of hepatocellular carcinoma S Ohrnberger, A Thavamani, A Braeuning, DB Lipka, M Kirilov, R Geffers, ... Hepatology 61 (3), 979-989, 2015 | 51 | 2015 |
| Cross-platform toxicogenomics for the prediction of non-genotoxic hepatocarcinogenesis in rat M Römer, J Eichner, U Metzger, MF Templin, S Plummer, ... PLoS ONE 9 (5), e97640, 2014 | 48 | 2014 |
| Translating immunopeptidomics to immunotherapy‐decision‐making for patient and personalized target selection J Fritsche, B Rakitsch, F Hoffgaard, M Römer, H Schuster, DJ Kowalewski, ... Proteomics 18 (12), 1700284, 2018 | 40 | 2018 |
| Influence of Feature Encoding and Choice of Classifier on Disease Risk Prediction in Genome-Wide Association Studies F Mittag, M Römer, A Zell PLoS ONE 10 (8), e0135832, 2015 | 29 | 2015 |
| Pitfalls in HLA ligandomics—how to catch a li (e) gand J Fritsche, DJ Kowalewski, L Backert, F Gwinner, S Dorner, M Priemer, ... Molecular & Cellular Proteomics 20, 2021 | 26 | 2021 |
| Tumor promotion and inhibition by phenobarbital in livers of conditional Apc-deficient mice A Braeuning, A Gavrilov, M Geissler, C Wenz, S Colnot, MF Templin, ... Archives of toxicology 90, 1481-1494, 2016 | 25 | 2016 |
| ZBIT Bioinformatics Toolbox: A Web-Platform for Systems Biology and Expression Data Analysis M Römer, J Eichner, A Dräger, C Wrzodek, F Wrzodek, A Zell PLoS ONE 11 (2), e0149263, 2016 | 24 | 2016 |
| Evaluation of Toxicogenomics Approaches for Assessing the Risk of Nongenotoxic Carcinogenicity in Rat Liver J Eichner, C Wrzodek, M Römer, H Ellinger-Ziegelbauer, A Zell PLoS ONE 9 (5), e97678, 2014 | 23 | 2014 |
| Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy GB Kim, J Fritsche, S Bunk, A Mahr, F Unverdorben, K Tosh, H Kong, ... Science translational medicine 14 (660), eabo6135, 2022 | 19 | 2022 |
| Epidermal growth factor represses constitutive androstane receptor expression in primary human hepatocytes and favors regulation by pregnane X receptor H De Boussac, C Gondeau, P Briolotti, C Duret, F Treindl, M Römer, ... Drug Metabolism and Disposition 46 (3), 223-236, 2018 | 12 | 2018 |
| ToxDBScan: large-scale similarity screening of toxicological databases for drug candidates M Römer, L Backert, J Eichner, A Zell International Journal of Molecular Sciences 15 (10), 19037-19055, 2014 | 9 | 2014 |
| Xenobiotic CAR Activators Induce Dlk1-Dio3 Locus Noncoding RNA Expression in Mouse Liver L Pouché, A Vitobello, M Römer, M Glogovac, AK MacLeod, ... Toxicological sciences 158 (2), 367-378, 2017 | 8 | 2017 |
| Immunotherapy with b* 07 restricted peptides and combination of peptides against cancers and related methods H Schuster, DJ Kowalewski, O Schoor, J Fritsche, T Weinschenk, H Singh, ... US Patent App. 17/472,290, 2022 | 4 | 2022 |
| Immunotherapy with b* 07 restricted peptides and combination of peptides against cancers and related methods H Schuster, DJ Kowalewski, O Schoor, J Fritsche, T Weinschenk, H Singh, ... US Patent App. 16/526,114, 2020 | 2 | 2020 |
| Mesenchyme-derived factors enhance preneoplastic growth by non-genotoxic carcinogens in rat liver M Nejabat, T Riegler, T Reitinger, S Subosits, M Römer, J Eichner, ... Archives of toxicology 92, 953-966, 2018 | 2 | 2018 |
| MARCARviz: Interactive web-platform for exploratory analysis of toxicogenomics data for nongenotoxic hepatocarcinogenesis M Römer, H Ellinger-Ziegelbauer, B Grasl-Kraupp, M Schwarz, A Zell PeerJ Preprints, 2016 | 2 | 2016 |
| Immunotherapy with B* 07 restricted peptides and combination of peptides against cancers and related methods H Schuster, DJ Kowalewski, O Schoor, J Fritsche, T Weinschenk, H Singh, ... US Patent 11,655,280, 2023 | 1 | 2023 |
| Amidated peptides and their deamidated counterparts displayed by non-hla-a* 02 for use in immunotherapy against different types of cancers J Hukelmann, H Schuster, L Wullkopf, C SCHRAEDER, J FRITSCHE, ... US Patent App. 18/544,048, 2024 | | 2024 |
| Amidated peptides and their deamidated counterparts displayed by non-hla-a* 02 for use in immunotherapy against different types of cancers J Hukelmann, H Schuster, L Wullkopf, C SCHRAEDER, J FRITSCHE, ... US Patent App. 18/529,644, 2024 | | 2024 |
| Amidated peptides and their deamidated counterparts displayed by non-HLA-A* 02 for use in immunotherapy against different types of cancers preliminary class J Hukelmann, H Schuster, L Wullkopf, C Schraeder, J Fritsche, ... US Patent 11,952,409, 2024 | | 2024 |
Andreas ZellProfessor für Informatik, Universität TübingenVerified email at uni-tuebingen.de
